199 related articles for article (PubMed ID: 28290887)
1. [Rivaroxaban at Non-Valvular Atrial Fibrillation: a Prospective Study and Clinical Practice].
Fonyakin AV
Kardiologiia; 2016 Aug; 56(8):87-92. PubMed ID: 28290887
[TBL] [Abstract][Full Text] [Related]
2. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; van Eickels M; Turpie AG
Vasc Health Risk Manag; 2014; 10():425-34. PubMed ID: 25083135
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
Spencer RJ; Amerena JV
Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
[TBL] [Abstract][Full Text] [Related]
4. [Rivaroxaban use in prevention of stroke in patients with non-valvular atrial fibrillation in clinical practice, results of observational studies and our experience].
Málek F
Vnitr Lek; 2016; 62(10):814-819. PubMed ID: 27900868
[TBL] [Abstract][Full Text] [Related]
5. [APPLICATION Rivaroxaban for Secondary Stroke Prevention in Clinical Practice. RESULTS OF RUSSIAN Prospective, Multicenter, Observational Study NEURO-XAR].
Fonyakin On Behalf Of The Working Group Of Researchers AV
Kardiologiia; 2016 Apr; 56(4):49-53. PubMed ID: 28294859
[TBL] [Abstract][Full Text] [Related]
6. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; Kuhls S; van Eickels M; Turpie AG;
Eur Heart J; 2016 Apr; 37(14):1145-53. PubMed ID: 26330425
[TBL] [Abstract][Full Text] [Related]
7. The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
Shimokawa H; Yamashita T; Uchiyama S; Kitazono T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Sakuma I; Saku K; Okumura Y; Nakamura Y; Morimoto H; Matsumoto N; Tsuchida A; Ako J; Sugishita N; Shimizu S; Atarashi H; Inoue H
Int J Cardiol; 2018 May; 258():126-132. PubMed ID: 29429636
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.
Barón-Esquivias G; Marín F; Sanmartín Fernandez M
Expert Rev Cardiovasc Ther; 2017 May; 15(5):403-413. PubMed ID: 28319424
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
Barón-Esquivias G; Fernández-Avilés F; Atienza F; Pastor Pueyo P; Toro R; Sanmartín Fernández M
Expert Rev Cardiovasc Ther; 2015 Apr; 13(4):341-53. PubMed ID: 25797900
[TBL] [Abstract][Full Text] [Related]
10. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
[TBL] [Abstract][Full Text] [Related]
11. Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation : Sub-analysis of the EXPAND Study.
Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
Heart Vessels; 2019 Jan; 34(1):141-150. PubMed ID: 29980835
[TBL] [Abstract][Full Text] [Related]
12. Global Prospective Safety Analysis of Rivaroxaban.
Kirchhof P; Radaideh G; Kim YH; Lanas F; Haas S; Amarenco P; Turpie AGG; Bach M; Lambelet M; Hess S; Camm AJ;
J Am Coll Cardiol; 2018 Jul; 72(2):141-153. PubMed ID: 29976287
[TBL] [Abstract][Full Text] [Related]
13. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
14. Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain.
Martí E; Segado A; Pastor-Galán I; Amat P; Remigia MJ; Solano C; Navarro B
Future Cardiol; 2018 May; 14(3s):3-8. PubMed ID: 29848095
[TBL] [Abstract][Full Text] [Related]
15. Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.
Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; Lambelet M; Bach M; Turpie AGG
Europace; 2019 Mar; 21(3):421-427. PubMed ID: 30052894
[TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes of rivaroxaban treatment in patients with nonvalvular atrial fibrillation and worsening renal function.
Nakagawara J; Ikeda T; Ogawa S; Kitazono T; Minematsu K; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
J Cardiol; 2019 Dec; 74(6):501-506. PubMed ID: 31371191
[TBL] [Abstract][Full Text] [Related]
17. Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.
Ikeda T; Atarashi H; Inoue H; Uchiyama S; Kitazono T; Yamashita T; Shimizu W; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Sakuma I; Saku K; Okumura Y; Nakamura Y; Morimoto H; Matsumoto N; Tsuchida A; Ako J; Sugishita N; Shimizu S; Shimokawa H
Tohoku J Exp Med; 2016 Dec; 240(4):259-268. PubMed ID: 27904005
[TBL] [Abstract][Full Text] [Related]
18. Clinical profile, adequacy of dosage and thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital of Asturias, Spain.
Muñiz Lobato S; Tarrazo Tarrazo C; González Fernández E; Morán Alcalá M
Future Cardiol; 2018 May; 14(3s):17-24. PubMed ID: 29848093
[TBL] [Abstract][Full Text] [Related]
19. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
Laliberté F; Cloutier M; Nelson WW; Coleman CI; Pilon D; Olson WH; Damaraju CV; Schein JR; Lefebvre P
Curr Med Res Opin; 2014 Jul; 30(7):1317-25. PubMed ID: 24650301
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry.
Caro Martinez C; Cerezo Manchado JJ; Flores Blanco PJ; Elvira Ruíz G; Albendín Iglesias H; Lova Navarro A; Arregui Montoya F; García Alberola A; Andrés Pascual Figal D; Bailén Lorenzo JL; Navarro-Almenzar B; García-Candel F; Manzano Fernández S
Curr Med Res Opin; 2019 Aug; 35(8):1463-1471. PubMed ID: 30912682
[No Abstract] [Full Text] [Related]
[Next] [New Search]
